Patients with osteoporosis: children of a lesser god
Giovanni Adami,
Maurizio Rossini,
Thomas Funck-Brentano,
Roland Chapurlat,
Elena Tsourdi
Affiliations
Giovanni Adami
Division of Rheumatology, University of Verona, Verona, Italy
Maurizio Rossini
Rheumatology Unit, University of Verona, Verona, Italy
Thomas Funck-Brentano
1INSERM U1132, Hôpital Lariboisière, Paris, France
Roland Chapurlat
Department of Rheumatology, Hospices Civils de Lyon, Lyon, France
Elena Tsourdi
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III & Center for Healthy Aging, Technical University Medical Center, Dresden, Germany
Osteoporosis is a common non-communicable disease with enormous societal costs. Antiosteoporosis medications have been proven efficacious in reducing the refracture rate and mortality; moreover, we have now convincing evidence about the cost-effectiveness of antiosteoporotic medications. However, albeit preventable and treatable, osteoporosis has been somehow neglected by health authorities. Drugs approval has been unnecessarily lengthy, especially when compared with other non-communicable diseases. Herein, we discuss the issue of procrastinating drug approval in osteoporosis and future implications.
